Exclusive: Financing for global health has never looked more dire as the world reels from Trump’s dramatic pullback. Now the biggest funder of programs against HIV, TB and malaria is looking to the UK and others to urgently raise $18 billion. Gift link: bloomberg.com/news/articles/…

Reliance on private hospitals by the NHS is helping patients get seen quicker than they otherwise would. But it's also fueling a two-track system, benefitting those with less complex conditions. Our big data story w/ Andre Tartar, Rachel Lavin is out: bloomberg.com/graphics/2025-…

AI drug developer Recursion Pharmaceuticals Inc. is considering an Amazon Prime-style subscription model for selling its pipeline of medicines. We spoke with CEO Chris Gibson this week at the company's King's Cross office about the idea. Gift link: bloomberg.com/news/articles/…

The US is withdrawing from global health alliances at a dangerous time trib.al/hUqqU6Y

The US is withdrawing from global health alliances at a dangerous time trib.al/PujAszc via Businessweek

Trump's dramatic remaking of global health means more people will die from preventable conditions, according to scientists and other experts interviewed by Bloomberg. “This is the worst scenario I can possibly imagine,” says virologist Angela Rasmussen. bloomberg.com/news/articles/…

SCOOP: WHO is asking employees to consider early retirement as it seeks to cut costs following Trump’s decision to withdraw. Staff aged 55 years old or older can retire with 4 months pay, according to copy of internal email seen by Bloomberg. Gift link: bloomberg.com/news/articles/…

The World Health Organization is asking some employees to consider early retirement in a bid to cut costs after Trump’s decision to withdraw trib.al/0VR1VaO

AstraZeneca to buy Belgian cell therapy biotech for up to $1B EsoBiotec's in vivo BCMA CAR-T is being tested in an investigator-initiated trial in China. The therapy is developed in collab with Shenzhen Pregene Biopharma bloomberg.com/news/articles/… via Ashleigh Furlong Bloomberg

Gavi's CEO Sania Nishtar isn't accepting the Trump administration's plan to terminate its funding without a fight. We interviewed Nishtar as she heads to Washington, hoping to persuade US to reverse a decision that threatens millions of lives. Gift link: bloomberg.com/news/articles/…

Progress in combating HIV/AIDS may be about to reverse as the Trump administration guts funding Ashleigh Furlong Janice Kew Jason Gale bloomberg.com/news/articles/… via @bbgequality

Cómo España se ha convertido en uno de los países favoritos (de todo el mundo) para las farmacéuticas bloomberg.com/news/articles/… Ashleigh Furlong, Clara Hernanz Lizarraga y Rodrigo Orihuela en Bloomberg Bloomberg

The pharma industry is flocking to Spain. We wanted to know why. The answer was fascinating: Tax breaks; cheap, good quality science and a government bending over backwards to attract investment. Story W/Clara Hernanz Lizarraga, Rodrigo Orihuela, Julia Han Janicki 🌻 Gift link: bloomberg.com/news/articles/…

🚨 NEW TOOL ALERT: Meet NudgeDetect 🚨 Ever felt nudged into clicking “Buy Now”, unknowingly subscribing, or paying hidden fees? NudgeDetect is a Chrome extension I’ve built to reveal ‘manipulative’ website tricks: and help you fight back. chromewebstore.google.com/detail/aodlboc… 1/5

Examples of what it catches: · FOMO (“Only 1 left!”) · Anchoring (“Original price £1,105. Current price £942”) · Hidden Costs (Drip pricing) ("Concert tickets from £20, final checkout price £37.50 after booking fees") · Upselling (“Buy a bundle”) · ...and many more 4/5

It’s free (up to 30 scans p/m) and totally anonymous. This tool is still very much in early stages, with some bugs – but any and all feedback welcomed. Let’s build a more honest internet. Happy NudgeDetecting! 🟢🟠🔴 5/5

Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion (while Blueprint was once focused on precision cancer therapies and still has an oncology pipeline, Sanofi's release has 0 mention of the cancer work) with Ashleigh Furlong Phoebe Sedgman bloomberg.com/news/articles/…

Current Heads of WHO Collaborating Centres back the Organization in a new open letter in The Lancet. thelancet.com/journals/lance…